Clinical Trial

Synergetic B-cell Immunomodulation in SLE - 2nd Study.

Study acronym: SynBioSe-2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In follow-up of the previous SynBioSe Study the present study is a randomized controlled trial designed to further investigate the long-term clinical and imunological efficacy of combination B-cell targeting by starting treatment with belimumab (anti-BAFF) followed by rituximab(anti-CD20) in lupus nephritis patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2018-11-16; most recent amendment 2024-10-15.
Status change: Recruiting → Active, Not Recruiting 2024-10-15
Trial Details
NCT Number NCT03747159
Lead Sponsor Leiden University Medical Center
Collaborators: Dutch Kidney Foundation, GlaxoSmithKline
Conditions Lupus Erythematosus, Systemic
Enrollment 70 participants
Start Date 2018-10-01
Primary Completion 2024-06-07 (estimated)
Study Completion 2026-06-07 (estimated)
Updated on ClinicalTrials.gov 2024-10-17